106 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
on commercial OXLUMO worldwide as of December 31, 2023.
R&D Highlights
Alnylam announces today updates to the statistical analysis plan for the HELIOS-B … & Development (R&D) Expenses
GAAP and non-GAAP R&D expenses increased during the three and twelve months ended December 31, 2023, compared to the same
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 Nov 23
Results of Operations and Financial Condition
8:10am
and in Japan and is now approved in 93 countries.
R&D Highlights
Reported positive topline results from the KARDIA-1 Phase 2 dose-ranging study … and pipeline progress at a virtual R&D Day on December 13, 2023.
Alnylam announces today that results from the KARDIA-1 Phase 2 dose-ranging study
8-K
EX-99.1
tmr2bor
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
d2v76n67 ctpt3yuzh
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
etmrmwdxlcz4go
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
d8y5pk4p4g bp08yat59
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
8p2do8wo8dv5uehl2
28 Jul 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
bugu8e0s
28 Apr 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
wfs38fjze5x flq
10 Feb 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
e8il4v74ptj7x0ccm
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
EX-99.1
4iknrr
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
EX-99.1
fc2kbmrjf8rfsd k50l
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am